Defining success for retinal gene therapy patients and payers

Parexel hosted an expert panel at the October 2025 American Academy of Ophthalmology (AAO) in Orlando to discuss the "real-world readiness" of gene therapies, offering critical advice for companies developing treatments for inherited retinal diseases (IRDs) and neovascular age-related macular degeneration (nAMD). Moderated by Parexel’s Bharti Arya, MRCOphth, Executive Director and Therapeutic Area Head of Ophthalmology, the panel included Sunil Gupta, M.D., Founder of Retina Specialty Institute and Co-Founder/CMO of US Retina, Patrick Symmonds, Pharm D., Vice President at Health Advances (a Parexel subsidiary), and Bryan L. Lam, M.D., Professor and Director at the Bascom Palmer Eye Institute.